Sign In
Buy CDNA
$38.37
-1.36 (-3.42%)
At Close: Jul 20, 2026
NEW YORK and NEW ORLEANS , March 14, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
CareDx Launches Two Expanded Indications for AlloSure Testing Services
07:05am, Tuesday, 11'th Mar 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of cl
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues
New Strong Buy Stocks for February 27th
07:10am, Thursday, 27'th Feb 2025
BCS, CDNA, PGR, EZPW and EVER have been added to the Zacks Rank #1 (Strong Buy) List on February 27, 2025.
CareDx, Inc (CDNA) Q4 2024 Earnings Call Transcript
10:01pm, Wednesday, 26'th Feb 2025
CareDx, Inc (NASDAQ:CDNA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President and Chief Executive Officer Ab
CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
08:00pm, Wednesday, 26'th Feb 2025
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stree
CareDx Announces Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Wednesday, 26'th Feb 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Financial Highlights Revenu
CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict
07:05am, Tuesday, 25'th Feb 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healt
Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
09:43am, Friday, 21'st Feb 2025
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, LLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for
CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients
07:05am, Thursday, 20'th Feb 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of cl
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of cl
CareDx to Report Fourth Quarter and Full Year 2024 Financial Results
07:05am, Tuesday, 11'th Feb 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healt
CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock?
04:26am, Tuesday, 11'th Feb 2025
CareDx (CDNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Final Trades: NRG Energy, MP Materials, CareDx and Applovin
02:08pm, Monday, 10'th Feb 2025
The Investment Committee give you their top stocks to watch for the second half.
Does CareDx (CDNA) Have the Potential to Rally 42.25% as Wall Street Analysts Expect?
10:55am, Wednesday, 05'th Feb 2025
The consensus price target hints at a 42.3% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
